Literature DB >> 1628916

On the discounting of gained life-years in cost-effectiveness analysis.

M Johannesson1.   

Abstract

A controversial issue in cost-effectiveness analysis is the discounting of gained life-years. What has not been realized, however, is that the different methods used for discounting this measurement provide fundamentally different results. The method used is seldom explicitly stated. In the present article the four main methods for the discounting of gained life-years are reviewed and compared. The conclusion is that if we wish to continue comparing results, researchers must employ the same methodology.

Mesh:

Year:  1992        PMID: 1628916     DOI: 10.1017/s026646230001357x

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  10 in total

Review 1.  An introduction to Markov modelling for economic evaluation.

Authors:  A Briggs; M Sculpher
Journal:  Pharmacoeconomics       Date:  1998-04       Impact factor: 4.981

2.  Cost-effectiveness analysis: obstacles to standardisation and its use in regulating pharmaceuticals.

Authors:  B R Luce
Journal:  Pharmacoeconomics       Date:  1993-01       Impact factor: 4.981

3.  Economic decision making in healthcare. A standard approach to discounting health outcomes.

Authors:  A L Hillman; M S Kim
Journal:  Pharmacoeconomics       Date:  1995-03       Impact factor: 4.981

Review 4.  Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases.

Authors:  Jasper M Bos; Philippe Beutels; Lieven Annemans; Maarten J Postma
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

5.  Discounting health effects in pharmacoeconomic evaluations: current controversies.

Authors:  J M Bos; Maarten J Postma; Lieven Annemans
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

6.  A review of cost-effectiveness analyses of hypertension treatment.

Authors:  M Johannesson; B Jönsson
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

7.  Cost-effectiveness of antihypertensive treatment: metoprolol versus thiazide diuretics.

Authors:  M Johannesson; J Wikstrand; B Jönsson; G Berglund; J Tuomilehto
Journal:  Pharmacoeconomics       Date:  1993-01       Impact factor: 4.981

8.  Cost savings associated with detection and treatment of diabetic eye disease.

Authors:  J C Javitt
Journal:  Pharmacoeconomics       Date:  1995       Impact factor: 4.981

9.  Quantifying the burden of disease: the technical basis for disability-adjusted life years.

Authors:  C J Murray
Journal:  Bull World Health Organ       Date:  1994       Impact factor: 9.408

Review 10.  Cost-effectiveness analysis in diagnosis of cardiac disease: overview of its rationale and method.

Authors:  R E Patterson
Journal:  J Nucl Cardiol       Date:  1996 Jul-Aug       Impact factor: 5.952

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.